ReviewmAbs
Full-length recombinant antibodies from
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- From Payload-First Toward Dual-Mechanism Antibody-Drug Conjugates.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities.Journal of hematology & oncology · 2026Review
- Aglycosylated Immunoglobulin G1 Fc Stabilized Through Disulfide Bond Addition Exhibits Compositional Homogeneity and Retains Fc γ Receptor IIIa/CD16a Binding.Antibodies (Basel, Switzerland) · 2026Article
- The Production and Purification of Therapeutic Antibodies: A Comprehensive Analysis of Process- and Product-Related Contaminants.Biomolecules · 2026Review
- Directional conjugation of monoclonal antibodies to nanoparticles using metal-free click chemistry.Nature protocols · 2026Review
- Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy.Immunologic research · 2026Review
- Chemically Defined Non-human Glycans Comprising Galactose-α1-3-Galactose (α-Gal) Epitopes Glycoengineered into the Fragment Antigen-Binding (Fab) Domain of Cetuximab Differentially Affect Human Anti-α-Gal Immunoglobulin E (IgE) Binding.ACS pharmacology & translational science · 2026Article
- Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation.Military Medical Research · 2026Review
- Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges.Frontiers in pharmacology · 2026Review
- Determinants of success and failure of antibody-based strategies against respiratory viruses: insights from RSV and SARS-CoV-2.Frontiers in immunology · 2026Review
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.Molecular biotechnology · 2025Review
- Bacteriophages, Antibiotics and Probiotics: Exploring the Microbial Battlefield of Colorectal Cancer.International journal of molecular sciences · 2025Review
- Facile expression of proteins with desired N-terminal amino acid via an engineered cysteine protease domain.Communications biology · 2025Article
- Plant-based production of monoclonal antibodies for rapid detection of Papaya ringspot virus.Physiology and molecular biology of plants : an international journal of functional plant biology · 2025Article
- Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in bacteria.Nature communications · 2025Article
- Purification of Human Immunoglobulin G with Bathophenanthroline-ZnAntibodies (Basel, Switzerland) · 2025Article
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Advancements in Escherichia coli secretion systems for enhanced recombinant protein production.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several antibody fragments and antibody fragment-fusion proteins produced in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.